Vivelle Dot Side Effects
Serious Adverse Side Effects
Vivelle Dot | Estradiol Transdermal Patch has many serious adverse side effects associated with it:
- Breast cancer
- Uterine cancer
- Stroke
- Heart attack
- Blood clots
- Dementia
- Gallbladder disease
- Ovarian cancer
- Breast lumps
- Unusual vaginal bleeding
- Dizziness and faintness
- Changes in speech
- Severe headaches
- Chest pain
- Shortness of breath
- Pains in your legs
- Changes in vision
- Vomiting
Common Adverse Side Effects
Less severe and more common adverse side effects include:
- Headache
- Breast pain
- Irregular vaginal bleeding or spotting
- Stomach/abdominal cramps and bloating
- Nausea and vomiting
Warnings & Recalls for Vivelle Dot
Contraindications
Some contraindications of
Vivelle Dot | Estradiol Transdermal Patch include:
- Abnormal vaginal bleeding
- Known, suspected or a history of breast cancer
- Known or suspected neoplasia which is dependent upon estrogen
- Active deep vein thrombosis
- Pulmonary embolism
- Active and recent stroke or heart attack
- Liver dysfunction or disease
- Hypersensitivity to this drug
- Known or suspected pregnancy
Who Should Not Take This Drug
Some warnings, preexisting conditions, and precautions that might hinder a patient’s ability to take
Vivelle Dot | Estradiol Transdermal Patch include:
Vivelle Dot Treatment and Use
Vivelle Dot | Estradiol Transdermal Patch is a drug that is prescribed to menopausal women to alleviate symptoms of menopause attached to it such as night sweats, severe hot flashes, vaginal dryness and vaginal atrophy. The drug company Novogyne Pharmaceuticals manufactures and markets Vivelle Dot | Estradiol Transdermal Patch. Estradiol is a sex hormone associated mainly with females, however it is also present in males as a byproduct of testosterone levels. As the name implies, this drug is administered in patch for an extended release effect.
The official FDA-labeled indications for this drug are for:
Non-FDA labeled indications for this drug include:
How This Drug Works
Estrogens are known to regulate the transcription of a limited amount of genes. They act by binding to the nuclear receptors of estrogen-responsive tissues of women. Estrogens are also known to moderate the pituitary secretion of gonadotropins, follicle stimulating hormones and also the luteinizing hormones. Estrogens do this through a negative feedback mechanism which reduces levels of these certain hormones evident in postmenopausal women. Estradiol is the primary intracellular human estrogen and is exponentially more potent than its metabolites at the receptor level.
Dosages
Vivelle Dot | Estradiol Transdermal Patch has five dosages of ranging from 0.025mg, 0.0375mg, 0.05mg, 0.075mg, and 0.1 mg depending upon the necessity of the patient to have higher dosages or not. The 0.025mg is exclusively for women who require Vivelle Dot | Estradiol Transdermal Patch for postmenopausal osteoporosis.
